ANTIVIRAL TECHNOLOGIES, INC. | 2013 | FY | 3


NOTE 2 UNCERTAINTY OF ABILITY TO CONTINUE AS A GOING CONCERN

 

The Company's financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not generated revenues since inception and has never paid any dividends and is unlikely to pay dividends or generate significant earnings in the immediate or foreseeable future. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain necessary equity financing to continue operations and the attainment of profitable operations.

 

As of December 31, 2013, the Company has not generated any revenue and has incurred an accumulated deficit since inception totaling $2,675,284 at December 31, 2013 and its current liabilities exceed its current assets by $3,166,257. These financial statements do not include any adjustments relating to the classification of liabilities that might be necessary should the Company be unable to continue as a going concern. These factors noted above raise substantial doubts regarding the Company's ability to continue as a going concern.


us-gaap:LiquidityDisclosureGoingConcernNote